Importantly, a remarkable delay in tumor growth and tumor shrinkage was observed after immunoliposomes administration, although full tumor regression was only observed in 20% of mice, similar to the previous observed for empty PD-L1 targeted liposomes but at a dose four times higher (100 μg/mouse) [30]. This evidence concerns the gene CD274 and neoplasm.